Oliver's mTOR Atlas Evidence Platform
Reading level
Mode

Michael N. Corradetti

As an MD-PhD student at the University of Michigan, was first author on the 2004 study linking the LKB1 tumour suppressor to TSC2 through AMPK. He is now a radiation oncologist

Medical director of radiation oncology, Providence Queen of the Valley Medical Center, Napa · residency, Hospital of the University of Pennsylvania · MD and PhD in Cell and Molecular Biology, University of Michigan · undergraduate, Harvard

Radiation Oncology, Providence Queen of the Valley Medical Center (Napa, California, USA) ↗

Michael Corradetti was first author of the Atlas study, from Kun-Liang Guan's lab at the University of Michigan Life Sciences Institute, showing that LKB1, the gene mutated in Peutz-Jeghers syndrome, lowers S6K and 4E-BP1 phosphorylation through AMPK and TSC2 (COR2004). Together with a parallel study by Shaw and colleagues it tied energy stress, via LKB1 and AMPK, to the TSC2-mTOR axis.

Corradetti completed an MD and a PhD in Cell and Molecular Biology at Michigan, with doctoral work on inherited cancer syndromes, then trained in radiation oncology at the University of Pennsylvania. He has published on radiotherapy for lung cancer and now practises as a radiation oncologist in Napa, California.

Milestones in the Atlas

A selection, not a full bibliography: only papers that meet the Atlas inclusion criteria.

YearEvidenceStudy
2004 M Regulation of the TSC pathway by LKB1: evidence of a molecular link between tuberous sclerosis complex and Peutz-Jeghers syndrome COR2004 First author: showed in cultured cells that LKB1 inhibits mTOR outputs through AMPK and TSC2.

Co-authors in the Atlas

People with a profile here who share at least one study with Michael N. Corradetti.

Every researcher with a profile →

← All researchers

Was this page useful?
Spotted something wrong or out of date about Michael N. Corradetti?